A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

NCT04257110 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced/Metastatic HER2 Positive Solid Tumors

Interventions

DRUG: BB-1701

Sponsor

Bliss Biopharmaceutical (Hangzhou) Co., Ltd